CAC
AZN icon

Cowen and Company’s AstraZeneca AZN Stock Holding History

Cowen and Company’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-21,706
Closed -$2.53M – 609
2021
Q4 		$2.53M Buy
21,706
+460
+2% +$54.1K 0.23% 92
2021
Q3 		$2.55M Buy
+21,246
New +$2.47M 0.12% 81

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Cowen and Company's AZN Position: Q1 2022 in Review

Cowen and Company sold out of AstraZeneca (AZN) in Q1 2022, closing a stake of 21,706 shares — an estimated $2.53M sold.

Cowen and Company first reported a position in AZN in Q3 2021 and held it in 2 quarters. The position peaked at $2.55M in Q3 2021. 981 funds tracked by Wall St. Rank hold AZN as of Q1 2022.

  • Cowen and Company reported no remaining AstraZeneca position as of Q1 2022 after selling out during the quarter.
  • Cowen and Company sold 21,706 AstraZeneca shares in Q1 2022, an estimated $2.53M.
  • Cowen and Company first reported a position in AstraZeneca in Q3 2021 and held it in 2 quarters.
  • Cowen and Company's AstraZeneca position peaked at $2.55M in Q3 2021.
  • 981 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2022.

Based on Cowen and Company's 13F filing for Q1 2022, filed 16 May 2022.